Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 536

1.

Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.

Hirashio S, Taguchi T, Naito T, Maki K, Ogata S, Taniyama K, Taniguchi Y, Yorioka N.

Clin Nephrol. 2009 May;71(5):550-6.

PMID:
19473616
[PubMed - indexed for MEDLINE]
2.

Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.

Mignani R, Cagnoli L.

J Nephrol. 2004 May-Jun;17(3):354-63. Review.

PMID:
15365954
[PubMed - indexed for MEDLINE]
3.

[Enzyme replacement therapy in Fabry's disease].

Alvarez L, del Pozo C, Trigueros M, Sánchez L, Albero MD, López-Menchero R, Ortega E.

Nefrologia. 2005;25(3):322-7. Spanish.

PMID:
16053014
[PubMed - indexed for MEDLINE]
4.

[Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].

Thomaidis T, Relle M, Reinke J, Beck M, Schwarting A.

Med Klin (Munich). 2009 Sep 15;104(9):699-703. doi: 10.1007/s00063-009-1152-1. Epub 2009 Sep 23. Review. German.

PMID:
19779674
[PubMed - indexed for MEDLINE]
5.

Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.

Desnick RJ.

Expert Opin Biol Ther. 2004 Jul;4(7):1167-76. Review.

PMID:
15268683
[PubMed - indexed for MEDLINE]
6.

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.

Lubanda JC, Anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Szymanska A.

Genet Med. 2009 Apr;11(4):256-64. doi: 10.1097/GIM.0b013e3181981d82.

PMID:
19265719
[PubMed - indexed for MEDLINE]
7.

[Fabry nephropathy in a female with superposed IgA glomerulonephritis].

Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B.

G Ital Nefrol. 2005 Jul-Aug;22(4):385-9. Italian.

PMID:
16267800
[PubMed - indexed for MEDLINE]
8.

Spotlight on agalsidase beta in Fabry disease.

Keating GM, Simpson D.

BioDrugs. 2007;21(4):269-71. Review.

PMID:
17628124
[PubMed - indexed for MEDLINE]
9.

[Intravenous enzyme substitution therapy in children with Fabry's disease].

Tøndel C, Laegreid LM, Hirth A, Houge G, Månsson JE, Søvik O.

Tidsskr Nor Laegeforen. 2003 Dec 4;123(23):3388-90. Norwegian.

PMID:
14713976
[PubMed - indexed for MEDLINE]
10.

Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease.

Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group.

N Engl J Med. 2001 Jul 5;345(1):9-16.

PMID:
11439963
[PubMed - indexed for MEDLINE]
Free Article
11.

Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

Tahir H, Jackson LL, Warnock DG.

J Am Soc Nephrol. 2007 Sep;18(9):2609-17. Epub 2007 Jul 26.

PMID:
17656478
[PubMed - indexed for MEDLINE]
Free Article
12.

Subclinical Fabry's disease occurring in the context of IgA nephropathy.

Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N.

Clin Nephrol. 1997 Feb;47(2):71-5.

PMID:
9049452
[PubMed - indexed for MEDLINE]
13.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N.

J Am Soc Nephrol. 2007 May;18(5):1547-57. Epub 2007 Apr 4.

PMID:
17409312
[PubMed - indexed for MEDLINE]
Free Article
14.

Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.

De Schoenmakere G, Chauveau D, Grünfeld JP.

Nephrol Dial Transplant. 2003 Jan;18(1):33-5.

PMID:
12480957
[PubMed - indexed for MEDLINE]
Free Article
15.

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.

Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T, Chiba Y, Takashiba M, Jigami Y, Fukushige T, Kanzaki T, Itoh K.

J Hum Genet. 2006;51(3):180-8. Epub 2005 Dec 22.

PMID:
16372133
[PubMed - indexed for MEDLINE]
16.

[Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].

Mignani R, Feriozzi S, Carraro G, Martinelli F, Cianciaruso B.

G Ital Nefrol. 2009 Sep-Oct;26(5):577-84. Review. Italian.

PMID:
19802803
[PubMed - indexed for MEDLINE]
17.

Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.

Masugata H, Senda S, Goda F, Yamagami A, Okuyama H, Kohno T, Hosomi N, Yukiiri K, Noma T, Murao K, Kohno M, Itoh S.

Tohoku J Exp Med. 2009 Mar;217(3):169-74.

PMID:
19282651
[PubMed - indexed for MEDLINE]
Free Article
18.

Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy.

Kato T, Nishimura K, Ichikawa Y.

Int J Urol. 2009 Jul;16(7):650. doi: 10.1111/j.1442-2042.2009.02321.x. No abstract available.

PMID:
19659805
[PubMed - indexed for MEDLINE]
19.

Fabry-like laminated myelin body associated with IgA nephropathy.

Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T.

Nihon Jinzo Gakkai Shi. 1994 Nov;36(11):1303-7.

PMID:
7853764
[PubMed - indexed for MEDLINE]
20.

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.

Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M.

Kidney Int. 2002 Dec;62(6):1933-46.

PMID:
12427118
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk